Ibogaine

Key Points

• Ibogaine is not FDA-approved as a treatment in the United States and remains Schedule I federally.
• Human evidence includes observational work and early clinical research, with important limitations and selection bias concerns.
• QT/QTc prolongation, arrhythmia risk, drug interactions, screening, and emergency readiness are central safety topics.
• Claims about cures, success rates, or guaranteed withdrawal interruption are checked against study design and source quality.

What Ibogaine Is

Ibogaine is a psychoactive indole alkaloid associated with Tabernanthe iboga and related plants. It is discussed in research on opioid withdrawal, substance-use disorders, traumatic brain injury, neuropsychiatric symptoms, and related mechanisms.

Ibogaine is not the same as whole-plant Iboga, Noribogaine, or newer analogs. Mixing those categories leads readers to mistake a plant tradition, an isolated alkaloid, a metabolite, and a drug-development program for the same thing.

Howard Lotsof and the 1962 Observation

Howard Lotsof belongs near the beginning of any modern Ibogaine history. In 1962, Lotsof, then 19 and using heroin, reported that Ibogaine unexpectedly interrupted withdrawal and craving. That personal observation helped launch modern Western interest in Ibogaine as a possible addiction-treatment intervention.

IbogaBase treats the Lotsof story as foundational history, not proof of cure or safety. It should be read alongside later observational studies, clinical-trial records, safety literature, patent history, and the wider Iboga cultural context.

Hunter S. Thompson, Ed Muskie, and Political Mythology

Ibogaine also appears in U.S. political-media history. During the 1972 presidential campaign, Hunter S. Thompson circulated and reported a rumor that Senator Edmund Muskie was using Ibogaine. Thompson later framed the episode as a test of campaign journalism and rumor circulation, not as a verified medical claim.

This belongs in the historical record because it shaped public mythology around Ibogaine. It does not belong in the evidence record as a real exposure, diagnosis, or pharmacology claim.

Mid-Century and Early Psychotherapeutic History

Ibogaine's Western history did not begin with Howard Lotsof. In the first half of the twentieth century, a Tabernanthe extract was sold in France under the name Lambarene as a stimulant tonic, and the pharmaceutical company CIBA studied ibogaine and related alkaloids. This mid-century ibogaine and iboga pharmacology is commercial and research history, not evidence of modern safety or effectiveness.

French chemist Robert Goutarel is linked to mid-century iboga and ibogaine research and to a later review of the pharmacodynamics and therapeutic applications of iboga and ibogaine; Goutarel ibogaine references are read as research history tied to publications.

Separately, the psychiatrist Claudio Naranjo described ibogaine psychotherapy in the 1960s, an early ibogaine use in Western psychotherapeutic writing summarized in his 1973 book The Healing Journey. Historical psychotherapeutic practice is not current medical evidence.

Current Evidence Status

• Opioid-related literature includes observational studies, detoxification reports, and registered clinical research.
• TBI and neuropsychiatric interest grew after a 30-person veteran observational study and later neurophysiology work, but those studies do not establish broad efficacy.
• Recent reviews continue to describe the evidence base as early, limited by small samples, uncontrolled designs, and safety concerns.

Clinical Status

• Ibogaine is not FDA-approved as a treatment in the United States.
• U.S. federal law still places Ibogaine in Schedule I.
• Research interest, state funding, an IND allowance, or clinic marketing does not equal FDA approval.

High-Value Sources

Continue reading

Reader Boundary

Educational reference material only; not medical advice, legal advice, dosing instruction, provider referral, or emergency guidance. Emergency, treatment, and legal decisions belong with qualified professionals and local emergency systems.